Department of Endocrinology, Guangdong Hospital of Integrated Traditional Chinese and Western Medicine, Foshan, China.
Front Endocrinol (Lausanne). 2022 Aug 19;13:962385. doi: 10.3389/fendo.2022.962385. eCollection 2022.
The dipeptidyl peptidase-4 inhibitor (DPP-4i) drugs, such as evogliptin, as the second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to facilitate insulin secretion by reducing glucagon and inhibiting glucagon like peptides. With a vague consensus, the advantageous and non-inferior effects of evogliptin relative to other DPP-4i drugs were recently demonstrated on hemoglobin A1c (HbA1c) levels and overall adverse events in T2DM patients. Thus, the aim was to evaluate the overall influence of evogliptin on HbA1c levels and the adverse events in T2DM patients compared to sitagliptin and linagliptin.
Complying with PRISMA guidelines, we conducted a systematic literature search in databases and a meta-analysis. Data about HbA1c levels and the adverse events of T2DM patients were collected and analyzed.
From 1,397 studies, we found five matched studies involving 845 subjects (mean age: 54.7 ± 3 years). The meta-analysis revealed that evogliptin was non-inferior to sitagliptin/linagliptin with a mean difference of 0.062 (95% CI: -0.092 to 0.215. I: 0%. = 0.431) regarding the HbA1c level reduction, and the risk ratio was -0.006 (95% CI: -0.272 to 0.260. I: 1.7%. = 0.966) regarding the adverse effects, indicating no significant difference between evogliptin and linagliptin or sitagliptin in affecting the HbA1c level and adverse effects.
The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.
二肽基肽酶-4 抑制剂（DPP-4i）药物，如依格列汀，作为 2 型糖尿病（T2DM）治疗的二线药物，已被报道通过降低胰高血糖素和抑制胰高血糖素样肽来促进胰岛素分泌。最近的研究结果表明，与其他 DPP-4i 药物相比，依格列汀在糖化血红蛋白（HbA1c）水平和 T2DM 患者总体不良事件方面具有优势和非劣效性，虽然存在一些模糊的共识。因此，本研究旨在评估与西他列汀和利格列汀相比，依格列汀对 T2DM 患者 HbA1c 水平和不良事件的总体影响。
根据 PRISMA 指南，我们在数据库中进行了系统的文献检索和荟萃分析。收集和分析了 T2DM 患者的 HbA1c 水平和不良事件的数据。
从 1397 项研究中，我们找到了五项匹配的研究，共涉及 845 名受试者（平均年龄：54.7 ± 3 岁）。荟萃分析显示，依格列汀在降低 HbA1c 水平方面与西他列汀/利格列汀非劣效，平均差异为 0.062（95%CI：-0.092 至 0.215，I²：0%， = 0.431），而在不良事件方面的风险比为-0.006（95%CI：-0.272 至 0.260，I²：1.7%， = 0.966），表明依格列汀与利格列汀或西他列汀在影响 HbA1c 水平和不良事件方面没有显著差异。
本研究提供了初步证据，表明依格列汀与其他 DPP-4i 药物（包括西他列汀和利格列汀）在控制 HbA1c 水平和不良事件方面具有相似的疗效。
